Argument:1. The rate at which new drugs are developed in Nation X hasn't changed much. I.e. if the rate of development was 15%, it is now 18%
2. Simultaneously, the cost of developing these drugs has increased a lot. I.e. initially it cost $1M to develop the drug, it now costs $10M to develop one
3. The patent system in nation X "insulates drug developers" i.e. it protects the company that develops the drug from its competitors.
4. The company that develops the new drug can sell it at whatever price it wants to. And, it doesn't even have to worry about any threat of competition
So all in all, because of such a strong patent system, companies invest a lot (and thus drive up development costs) in the R&D of new drugs so
that they can later sell these drugs at whatever price they want for however long they want to.Conclusion: If the patent system reduces the time duration for which these companies can sell their drugs then the cost (investment in R&D) will reduce.
Pre-thinking: What if even after the reduction in time duration of the patent protection, the companies have an incentive to invest a lot in R&D of new drugs? Then in that case even with a limited duration of patent protection, the companies will continue to drive up the cost of development
Assumption: Once the time duration of patent protection is reduced, the companies will have no incentive to invest how they currently do in the development of new drugs
Quote:
A. In Nation X, current patent protections create impediments to the development of new drugs.
Incorrect: Whether the current patent system creates some challenges for the development process doesn't affect the conclusion. If we negate this choice we get "the current protections DO NOT create impediments to the development of new drugs". The negation does not break out the conclusion.
Quote:
B. If the prices of newly developed drugs were subject to market pressures sooner, companies would have a greater incentive to minimize research costs.
Correct: By reducing the protection time of the patents, the drug companies are motivated to minimize their research and thus the cost of development will be reduced. If we negate (B) we get "If the prices of newly developed drugs were subject to market pressures sooner, companies would NOT have a GREATER incentive to minimize research costs." So if they don't have an incentive greater than what they get with protection (even with its limited time period) then they would continue to invest and thus the cost of development will not drop. The negation of (B) breaks the argument
Quote:
C. If the prices of newly developed drugs were subject to market pressures sooner, pharmaceutical companies would have a greater incentive to increase the number of drugs they develop.
Incorrect: Irrelevant. The number of drugs is not of concern. All we care about is the overall cost of development. We want the companies t reduce the cost of development and not increase the number of drugs developed. In fact, it is likely that as the number of drugs increases, the cost of development will increase. So this choice (could possibly) break the conclusion
Quote:
D. Nation X's current patent system causes some pharmaceutical companies to exaggerate their research costs to consumers.
Incorrect: Some companies lie about the cost of development. Even if that's the case, how does this fact help us understand whether the reduction in patent protection time will help us reduce the cost of development?
Quote:
E. If the prices of newly developed drugs were subject to market pressures sooner, pharmaceutical companies would have a greater incentive to develop the most medically necessary new drugs.
Incorrect: Does producing medically necessary new drugs translate to a reduction in research cost/cost of development of new drugs? We have no information that could help us understand this connection
Correct: (C)